Intranasal Schirmer Test Shows Promise in Allergy Diagnosis
The intranasal Schirmer test (INSCH) may help detect allergic rhinitis during a nasal provocation test. Among patients with allergic rhinitis, the INSCH revealed significantly increased nasal secretions upon exposure to relevant allergens such as mites or birch. METHODOLOGY: The INSCH was performed by attaching Schirmer filter paper — widely used in ophthalmology to measure tears — to each nostril.
To investigate whether INSCH could objectively assess rhinorrhea during evaluations for allergy, the researchers recruited 50 participants from March 2023 to March 2024.
Half the participants underwent nasal provocation testing after they had a negative or borderline result for a tested allergen on a skin prick test or specific serum immunoglobulin E test. The other half were in a control group with no history of allergy. TAKEAWAY: Among patients with allergic rhinitis, INSCH wetting distance in significantly increased in the nostril that was provoked with an allergen (mean difference, 13.95 mm; P = .01).
= .01). Individuals with nonallergic rhinitis showed no change in nasal secretions upon provocation with a potential allergen.
A difference in wetting distance of at least 2.75 mm after provocation had a sensitivity of 81.8% and a specificity of 71.4% in detecting allergic rhinitis. IN PRACTICE:
'The INSCH could serve as a simple tool in everyday clinical practice to quickly objectify nasal secretion,' the authors wrote. SOURCE:
Paula von der Lage, MD, with the University of Zurich, Zurich, Switzerland, was the corresponding author of the study, which was published online on May 17 in Annals of Allergy, Asthma and Immunology . LIMITATIONS:
The study included patients who smoke, despite evidence that smoking can lead to drier nasal mucosa. DISCLOSURES:
The study received support from the Theodor und Ida Herzog-Egli-Stiftung, Switzerland.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape Medical News © 2025 WebMD, LLC
Cite this: Intranasal Schirmer Test Shows Promise in Allergy Diagnosis - Medscape - May 23, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
HealthX Intelligence Conference 2025: The Premier Event for Healthcare Professionals Looking to Stay at the Cutting Edge of Technology (London, United Kingdom - September 17-18, 2025)
Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "HealthX Intelligence 2025" conference has been added to offering. The HealthX Intelligence 2025 conference is the premier event for healthcare professionals looking to stay at the cutting edge of technology. This two-day event features keynote speakers from top technology companies, hospitals & healthcare providers, pharmaceutical companies, investors, government agencies, and tech start-ups and the event will provide attendees with an immersive experience that explores how artificial intelligence, automation, machine learning and data analytics can be used to revolutionize healthcare delivery and patient care. From emerging technologies to successful implementations, this unique conference provides valuable insights into current trends in healthcare innovation. Participants will have the opportunity to explore various case studies, present their research findings, interact with experts in the field, and develop new collaborations. Additionally, they can learn about emerging technologies that could potentially revolutionize healthcare delivery systems in the years ahead. With HealthX Intelligence 2025, you'll have the knowledge and tools to ensure that your organization is well-prepared for what lies ahead in the world of healthcare. Join us to experience the possibilities for Healthcare Innovation in 2025 and beyond. KEY DISCUSSIONS WE'LL BE EXPLORING Digital Health Adoption & Implementation Strategies Artificial intelligence (AI) in health systems Machine learning and deep learning applications Health Data analytics and predictive modelling Utilizing Big Data for More Effective Population Health Management Cloud Technologies Automation and robotics in healthcare delivery Intelligent medical devices and wearable technology Electronic health records (EHR) and healthcare information systems Telemedicine and remote patient monitoring Clinical decision support systems Natural language processing (NLP) and voice recognition in healthcare Health data privacy and security in the age of automation Patient engagement and personalized medicine Healthcare process optimization and workflow automation Internet of Medical Things (IoMT) and connected healthcare Blockchain applications in healthcare Integrated Care Platforms Ethical and regulatory considerations in healthcare automation Digital Leadership Impact of Technology in Home Healthcare Who Should Attend: Healthcare Professionals Technology Experts Healthcare Providers Investors & Government Agencies Tech Startups Researchers in Artificial Intelligence and Automation Data Analysts & Analytics Specialists Clinical Managers & Administrators Wearable Technology Developers IT Professionals Working With Big Data Robotics Engineers Medical Device Manufacturers Entrepreneurs Pursuing Innovative Solutions in the Healthcare Industry For more information about this conference visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Health Line
an hour ago
- Health Line
How Much Caffeine Does Tea Have Compared with Coffee?
While black tea, espresso, and coffee bring the most caffeine to the table, green tea packs a moderate amount as well. The content in white teas varies greatly, while herbal teas are practically caffeine-free. Caffeine's popularity as a natural stimulant is unparalleled. It's found in over 60 plant species and enjoyed across the globe, especially in coffee, chocolate, and tea. The caffeine content in a beverage varies depending on the ingredients and how the drink is prepared. While caffeine is considered safe, drinking too much may raise some concerns. Let's compare the caffeine contents of various teas and coffees and explore which drink you should choose. Why is caffeine a concern? An estimated 80% of the world's population enjoys a caffeinated product daily. Both the U.S. Department of Agriculture (USDA) and European Food Safety Authority (EFSA) define a safe caffeine intake as up to 400 mg per day, 200 mg per single dose, or 1.4 mg per pound (3 mg per kg) of body weight. Due to its stimulating effects, caffeine has been linked to health benefits like enhanced alertness, improved athletic performance, elevated mood, and increased metabolism. That said, consuming high amounts — such as single doses over 500 mg — may raise some concerns. In large doses, caffeine has been associated with anxiety, restlessness, and difficulty sleeping. In addition, a 2019 study suggests that drinking it regularly, even in moderate amounts, can cause chronic headaches and migraine episodes. Furthermore, caffeine is considered mildly addictive, and some people may be more susceptible to developing a dependence. Caffeine content varies by beverage type and preparation The amount of caffeine in tea or coffee can vary significantly depending on the origin, type, and preparation of the drink. Tea leaves contain 4% caffeine, while coffee beans have 0.9% to 2.6%. However, the coffee brewing process uses hotter water, which extracts more of the caffeine from the beans. Typically, you also use more coffee beans than you'd use tea leaves for a drink. Therefore, 1 cup (237 ml) of brewed coffee generally has more caffeine than a cup of tea. Tea varieties Black, green, and white teas are prepared from leaves of the same plant, Camellia sinensis. What sets them apart is the time of harvest and level of oxidation of the leaves. Black tea leaves are oxidized (especially exposed to oxygen for a longer amount of time), while white and green tea leaves are not. This gives black tea a characteristic bold and sharp flavor. An average cup (220 ml) of black tea packs 50 mg of caffeine but can contain more. For comparison, green teas contain up to 45 mg, while white teas deliver an average of 16.79 mg per gram (mg/g). According to some studies, white tea contains less caffeine than green tea. Matcha green tea is another high-caffeine tea. It usually comes in powdered form and packs 18.9 to 44.4 mg of caffeine per half-teaspoon (1-gram) serving. Similarly, yerba mate, a tea traditionally enjoyed in South America that's made by steeping the twigs and leaves of the Ilex paraguariensis plant, usually contains about 80 mg of caffeine per cup. While technically not made from tea leaves, herbal teas are a nice caffeine-free beverage choice. Tea preparation The preparation method greatly impacts the caffeine content of tea. Teas that steep for longer and in hotter water tend to produce a more potent cup. One 2024 study concluded that the best conditions to extract caffeine were at 212°F (100°C) for 30 minutes. The researchers extracted: 0.089 g of caffeine from black tea 0.06 g from used black tea 0.08 g from green tea 0.047 g from used green tea Coffee varieties An average 8-ounce (237-ml) cup of coffee contains 90 to 200 mg of caffeine. It's a common belief that coffee made from dark-roasted beans has more caffeine than coffee from light-roasted beans. However, since caffeine isn't affected much by roasting, this may not be the case. That said, since dark roast coffees are less dense than light roast ones, you may use greater amounts of beans or grounds when brewing this type, yielding more caffeine per cup. Espresso is a more concentrated source of caffeine. A single shot of espresso has about 127 mg of caffeine. Some specialty coffee drinks, such as lattes and cappuccinos, are made with a double shot of espresso. Coffee preparation Hot water draws more caffeine out of tea leaves in a shorter period of time, and the same holds for coffee. Coffee is typically brewed at a temperature of about 195 to 205°F (90 to 96°C). You can also make cold-brewed coffee by soaking ground coffee in cold, filtered water for 8 to 24 hours. As you use 1.5 times more ground coffee using this method compared with regular hot-water brewing, it may result in a more caffeinated cup. Which one should you drink? Caffeine acts quickly — usually within 45 minutes of consumption. If you're sensitive to the effects of caffeine, consider sticking to teas lower in caffeine like white or herbal teas. You may also brew high-caffeine teas for a shorter time, such as 1 minute instead of 3. Opting for decaffeinated tea or coffee is also a good way to enjoy these drinks without much caffeine. On the contrary, if you're a fan of high-caffeine drinks, you may enjoy espresso, cold-brew coffee, and teas with higher caffeine contents, including green and black varieties. To stay within safe amounts, drink no more than 400 mg daily, or 200 mg of caffeine at a time. This translates to no more than three to five 8-ounce (237 ml) cups of regular coffee daily, or eight 1-ounce (30-ml) shots of espresso. Those who have heart disease, are prone to migraine episodes, and take certain medications should limit their caffeine intake.
Yahoo
an hour ago
- Yahoo
World must ‘start screening for prostate cancer to stop men being left behind'
Every country should have a strategy for tackling prostate cancer with dedicated screening programs for men over 50, a leading health charity has said. Global Action on Men's Health, the leading international charity for men's health, is calling for prostate cancer – now the third most common cancer worldwide – to be dramatically elevated on the health agenda. On Monday it will launch a campaign to encourage all countries with adequate resources, including the UK, to launch national screening for the disease in a bid to cut unnecessary deaths. It will also call for the World Health Organization (WHO) to introduce a Global Prostate Cancer Initiative which 'covers every stage of the prostate cancer pathway from prevention to palliative care'. Prostate cancer is now the most frequently diagnosed cancer in men in 112 countries and the leading cause of cancer death among men in 48 countries. In England, it is now the most common cancer, killing some 12,000 men every year, according to Prostate Cancer UK. Writing in today's Telegraph, Peter Baker, the director of Global Action on Men's Health, said that men were being short-changed when it comes to healthcare. 'Men's health has been neglected for far too long with devastating consequences,' he writes. 'Globally, men's life expectancy lags five years behind women's. Men are significantly more likely to develop and die from cancer, heart disease, diabetes and tuberculosis. They are also at much greater risk of dying from suicide or an accident on the roads or at work.' Mr Baker calls for reform across health care systems – ensuring men have better access to GPs, for instance – and believes that a focus on prostate cancer is a good place to start. Rapid advances in screening technologies now mean that developed nations should soon be able to launch screening programs that will cut death rates by a third or more and reduce the dramatic social inequalities associated with the disease. Men with a family history of prostate cancer run a significantly higher genetic risk of developing prostate cancer, as do black men. Men from lower socioeconomic backgrounds are also much harder hit, due to a combination of poor health literacy and access to healthcare. The European Commission recently recommended introducing national prostate cancer screening across all 27 member states of the European Union, and already countries including Sweden and Norway have either launched or are on the brink of launching national screening programs. While blood tests for prostate cancer, known as prostate-specific antigen tests (PSA), have been available for many years, they throw up a large number of false positives. This in turn led to many unnecessary prostate removals and biopsies being performed, meaning the risks outweighed the benefits of running national screening programmes. But now, with the advent of more specific blood tests and high resolution MRI scans, which allow for much more accurate biopsies, the balance has changed, with several high quality studies showing the benefit of screening. The largest of these studies was the European Randomised Study of Screening for Prostate Cancer (ERSPC), which included over 182,000 men and showed a 20 per cent reduction in prostate cancer mortality among those screened. Another study in Gothenburg, Sweden, found that after 18 years of follow-up, men in the screening group were 35 per cent less likely to die from prostate cancer than men who were not screened. Men who started screening at age 55-59 were 53 per cent less likely to die. Professor Jonas Hugosson, a urologist at University of Gothenburg in Sweden who led the Swedish study, said he expected national screening for prostate cancer to be rolled out across most western European nations in the next few years. In Sweden a move to nationwide screening was already progressing and in Norway he expected a national screening program to be announced shortly, he said. However, just as with the roll out of breast cancer screening more than three decades ago, it would take most countries many years to gear up. 'In my view, we have quite a new situation today, and I think it's time for the health authorities to take a new standpoint,' he said. 'I'm quite sure about that and we will see screening come all over Europe during the coming years, but it takes 10 years to build up, at least.' The NHS in England does not have a dedicated men's health strategy but one has been promised by the end of the year by the new Health Secretary, Wes Streeting. Although the new strategy is unlikely to include the imminent launch of a national screening program for prostate cancer – the UK currently does not have the MRI machines and trained staff needed to launch one – it may include screening for high risk groups. These include black men, who have double the normal risk, and men with a family history of prostate and related cancers – including breast and ovarian cancer on the female side. In October last year, six-time Olympic cycling champion Sir Chris Hoy, 49, revealed that he had terminal prostate cancer. Both his father and grandfather had the disease but his was not caught by early testing, sparking an outcry. 'The rapid rise in prostate cancer cases is not just alarming, it is also unnecessary and therefore unacceptable,' said Global Action on Men's Health. 'Prostate cancer is currently inadequately addressed in global and national cancer policies'. In addition to national testing where possible, the charity is calling for the WHO to support a new Global Prostate Cancer Initiative covering 10 areas. These include governments being urged to introduce national cancer plans which specifically address prostate cancer with clear performance indicators, education programmes to raise awareness and tackle stigma, and investments in research, infrastructure, workforce development and treatments for prostate cancer. The WHO does not currently have a programme that focuses specifically on prostate cancer but 'integrates' it to its wider program for tackling cancer more generally. Cervical cancer, in contrast, has a dedicated programme dedicated to its global eradication but that is because the HPV vaccine makes it possible to wipe out the disease completely. Dr André Ilbawi, technical lead for cancer control at the WHO, welcomed the prostate campaign launched by Global Action on Men's Health, and said the disease was moving up the WHO's agenda. The organisation had just five countries involved in its cancer programme in 2015 to but has 100 today. 'We see prostate cancer as a priority and, in 2023, elevated it in our guidance because it can be treated,' said Dr IIbawi. 'If treatment is available, survival is extremely high. And if treatments are not available, those men will die. 'We agree that prostate cancer should be seen in the cancer agenda as high impact, cost-effective and meeting community needs'. Protect yourself and your family by learning more about Global Health Security Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
